HMG co-reductase expression and response to intravesical Bacillus Calmette-Guérin in patients with high grade non-muscle invasive urinary bladder cancer receiving statins

Jamie Krishnan (Lead / Corresponding author), Andrew Symington, Neil Kernohan, Suan Bray, Allison Robertson, Ghulam Nabi

Research output: Contribution to journalArticlepeer-review

Abstract

Background
Cardiovascular disease affects over 7 million people in the UK and statins are often prescribed to mitigate cardiovascular risks. The effect of statins on a number of cancers is debated and their effect on Bacillus Calmette-Guérin (BCG) responsiveness in non-muscle invasive urinary bladder cancer (NMIBC) is not fully understood.
Aims
This study aims to explore the difference in HMG Co-A reductase (HMGCR) expression in NMIBC on immunochemistry in BCG responders and non-responders while on statins.
Method
Three hundred and thirty-two cases of intravesical BCG treatment for high-risk NMIBC between November 2003 and December 2017 were identified. Patients taking statins for at least 12 months before the diagnosis of NIMBC and with a follow-up of at least 5 years were included. They were divided into BCG responders and non-responders. Tumour tissue from these patients was immunohistochemically stained and quantitative image analysis carried out to assess and compare HMGCR expression in the groups.
Results & Conclusion
This study showed a differential expression of HMGCR in responders vs. non-responders to BCG for high-risk NMIBC on statins. This data should form the basis of a further research and multi-centre study in a larger cohort, using HMGCR as a biomarker of response in patients on statins.
Original languageEnglish
Number of pages7
JournalScottish Medical Journal
Early online date13 Nov 2023
DOIs
Publication statusE-pub ahead of print - 13 Nov 2023

Keywords

  • Urinary bladder
  • cancer
  • HMG co-reductase
  • cholesterol
  • BCG

Fingerprint

Dive into the research topics of 'HMG co-reductase expression and response to intravesical Bacillus Calmette-Guérin in patients with high grade non-muscle invasive urinary bladder cancer receiving statins'. Together they form a unique fingerprint.

Cite this